

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following statements is true regarding the eligibility criteria for the Phase III POLO trial evaluating maintenance olaparib for patients with mPC who had not experienced disease progression on first-line platinum-based chemotherapy?
 - All eligible patients had germline BRCA mutations
 - Eligible patients had either somatic or germline BRCA mutations
- Which of the following observations is true regarding the severity and frequency of side effects associated with PARP inhibitors?
 - They are worse later in the treatment course
 - They are worse early in the treatment course and improve with time
- The Phase III AFACT trial comparing adjuvant gemcitabine/*nab* paclitaxel to gemcitabine alone for surgically resected pancreatic cancer reported which result with gemcitabine/*nab* paclitaxel with respect to the primary endpoint of disease-free survival by independent review?
 - Statistically significant improvement
 - No statistically significant improvement
- Approximately what percentage of patients with pancreatic cancer have BRCA mutations?
 - 3% to 10%
 - 18% to 25%
 - 30% to 50%
- What is the mechanism of action of the FDA-approved agent entrectinib?
 - MET inhibition
 - EGFR and HER2 inhibition
 - NTRK and ROS1 inhibition
 - RET inhibition
- Initial results from the Know Your Tumor program that matched patients with appropriate clinical trials according to actionable molecular alterations reported which result for patients who received molecularly matched therapy?
 - A significant improvement in overall survival
 - No significant improvement in overall survival
- Which of the following statements is true about liquid biopsies in the detection of mutations associated with cancer?
 - No specificity or sensitivity limitations have been reported
 - Lack of high specificity is an important limitation
- Which of the following observations regarding the tolerability of olaparib versus placebo was reported among the recently published results of the POLO trial assessing olaparib as maintenance therapy for patients with mPC?
 - A significantly worse quality of life with olaparib
 - A significantly worse quality of life with placebo
 - No difference in the quality of life between the arms
- High microsatellite instability _____ a predictor of response to immune checkpoint inhibitors in patients with pancreatic cancer.
 - Is
 - Is not
- Which of the following side effects are most frequently observed with olaparib?
 - Gastrointestinal and cardiovascular disorders
 - Gastrointestinal disorders, myelosuppression